Thousand Oaks-based Amgen, one of the largest biotechnology companies in the world, issued fiscal guidance for 2022 on Feb. 8 and shared plans to repurchase $6 billion of its shares in the first quarter of this year. In fiscal year 2022, Amgen expects revenue to be between $25.4 and $26.5 billion, with non-GAAP earnings per…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
